The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

脑淀粉样血管病（cerebral amyloid angiopathy，CAA）是一种常见的脑小血管病 ，其特征性病变是β-淀粉样蛋白（amyloid β-protein，Aβ）在大脑皮质及覆盖其上的软脑膜的中小动脉、微细动脉和毛细血管管壁渐进性沉积 ...

One of the major components of these protein buildups was thought to be a protein called amyloid beta, or Aβ42, which clump together into what is known as amyloid plaques. However, a new study ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

How exactly do amyloid plaques affect surrounding brain tissue ... “This is an important contribution that directly links the age of aggregated protein with overall disease pathology—reinforcing that ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Amyloid fibrils appear in many neurodegenerative ... When the group mutated any of these three amino acids in purified protein experiments, the mutant synucleins packed together much faster ...

A ground-breaking drug designed to delay the onset of Alzheimer's Disease has been approved for use within the EU, it is ...

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood ...